Avalo Therapeutics, Inc.

As of July 8, 2024, Avalo Therapeutics, Inc. is considered overvalued with key ratios indicating insufficient value generation, despite a strong year-to-date stock performance, and a concerning long-term return of -99.85%.

As of August 12, 2024, Avalo Therapeutics, Inc. is considered overvalued and has deteriorated to a "does not qualify" grade due to negative financial metrics, including a Price to Book Value of 0.36 and significant underperformance with a return of -63.27% over the past year.

As of May 30, 2025, Avalo Therapeutics, Inc. exhibits a mildly bearish trend, influenced by daily moving averages and weekly KST showing bearish momentum, despite some mildly bullish signals from the MACD.

As of March 2022, Avalo Therapeutics, Inc.'s management team includes Dr. Sol Barer (Chairman), Mr. Michael Cola (CEO and Director), and Directors Dr. Suzanne Bruhn, Mr. Joseph Miller, Mr. Steven Boyd, Mr. Phil Gutry, and Dr. Gilla Kaplan, with Boyd, Gutry, and Kaplan serving as Independent Directors.

Avalo Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for pediatric and orphan diseases. As of March 2025, it has a market cap of $48.40 million and reported a net profit loss of $13 million.

As of Jun 18, Avalo Therapeutics, Inc. has a market capitalization of 48.40 million, with net sales of 0.44 million and a net profit of 73.01 million over the latest four quarters. The company reported shareholder's funds of 133.03 million and total assets of 150.73 million as of Dec 24.